SV Health Investors, fresh off a $250 million fund for dementia-focused biotechs, has unveiled its latest effort, this time ...
Vertex halts VX-264 diabetes cell therapy due to poor efficacy in Phase 1/2 study, but continues Phase 3 trial of zimislecel ...
Welcome back to Endpoints Weekly, where we recap the week’s biggest news from the biopharma industry. Let’s start in DC. The ...
After a 6-year run, CRISPR Therapeutics COO Julianne Bruno is stepping out the door to pursue other opportunities. Bruno's ...
Highbridge Capital & Ayrmid offer $45M to buy bluebird bio, topping Carlyle/SK Capital's $29M bid, with additional payment ...
Alpha Lee announced a Zika virus-fighting molecule at a chemistry meeting, but later learned his $67M federal funding was cut due to pandemic's end, affecting multiple antiviral research programs.
Lykos Therapeutics’ interim CEO Michael Mullette is planning to step down, according to a source familiar with the decision.
Judge tosses Amgen's challenge to Colorado drug review board, says suit is 'too speculative'
A federal judge on Friday dismissed Amgen’s lawsuit against Colorado's drug affordability board and its decision to place a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback